ERBB2 and breast carcinoma: A recent sub-study by Ryu et al., 2021 [289], from a prospective, randomized phase III clinical trial of seven centers, was conducted with 123 HER2-negative breast cancer patients and identified differences in the metabolic and immunologic profiles as well as NLRs in patients treated with neoadjuvant chemotherapy (NCT) or neoadjuvant endocrine therapy (NET).